Universal Screening for BRCA1 and BRCA2 Mutations

Video

For High-Definition, Click

It has been suggested that all women should be screened for the BRCA1 and BRCA2 mutations in the course of routine medical care, notes Maurie Markman, MD. Ovarian cancer is rare, and routine screening for the general population is not warranted at this time, comments Michael J. Birrer, MD. If the general population were to be screened, appropriate follow-up and genetic counseling would need to be offered to all women who test positive, adds Warner K. Huh, MD.

Robert A. Burger, MD, remarks that factors such as family history and ethnicity should be considered when selecting patients for screening. Universal screening may be warranted in segments of the population with a high prevalence of disease, for example, women of Ashkenazi Jewish descent.

Related Videos
Naomi Adjei, MD, MPH, MSEd, gynecologic oncology fellow, The University of Texas MD Anderson Cancer Center
Rebecca Kristeleit, BSc, MBChB, MRCP, PhD
Abdulrahman Sinno, MD
Erin K. Crane, MD, MPH
Núria Agustí Garcia, MD
Sangeeta Goswami, MD, PhD, of The University of Texas MD Anderson Cancer Center
Gabriella Smith, MD
Shannon N. Westin, MD, MPH, FACOG, director, Early Drug Development, clinical medical director, professor, Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, codirector, Ovarian Cancer Moonshot Program, The University of Texas MD Anderson Cancer Center
Amin Nassar, MD